Related Experiment Video
Updated: May 16, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
The novel anticoagulants: the surgeons' prospective
Fadi E Shamoun1, Elvis N Martin, Samuel R Money
1Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA. Shamoun.fadi@mayo.edu
Surgery
|December 11, 2012
Summary
New anticoagulants like dabigatran, rivaroxaban, apixaban, and edoxaban are emerging for atrial fibrillation and venous thromboembolism. Their use requires careful consideration in patients undergoing surgery.
Area of Science:
- Pharmacology and Therapeutics
- Cardiovascular Medicine
- Hematology
Background:
- Anticoagulant medications present challenges in managing patients requiring operative interventions.
- Nonvalvular atrial fibrillation and venous thromboembolism are common conditions requiring anticoagulation.
- Existing anticoagulants have limitations necessitating the development of newer agents.
Purpose of the Study:
- To review recently introduced and investigational novel oral anticoagulants.
- To discuss the implications of these new agents for patients undergoing surgery.
- To provide an overview of dabigatran, rivaroxaban, apixaban, and edoxaban.
Main Methods:
- Literature review of new anticoagulant agents.
- Analysis of clinical data for dabigatran, rivaroxaban, apixaban, and edoxaban.
- Focus on applications in nonvalvular atrial fibrillation and venous thromboembolism prophylaxis.
Main Results:
- Dabigatran, rivaroxaban, apixaban, and edoxaban represent a new class of oral anticoagulants.
- These agents offer potential advantages but also require specific management strategies.
- Their introduction impacts the perioperative care of patients on anticoagulation.
Conclusions:
- Novel anticoagulants are increasingly used for nonvalvular atrial fibrillation and venous thromboembolism.
- Effective perioperative management strategies are crucial for patients on these new drugs.
- Further research and clinical experience are needed to optimize their use.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Aneurysm IV: Nursing Management
Vigilant monitoring for aneurysm rupture is essential for patients undergoing aortic surgery.Preoperative Nursing ManagementContinuously monitor the patient for manifestations of aneurysm rupture, such as pallor, weakness, tachycardia, hypotension, abdominal, back, groin, or periumbilical pain, changes in consciousness, and a pulsating abdominal mass. Regularly assess the patient's peripheral pulses.Instruct the patient to consume a clear liquid diet the day before surgery and administer...
01:23Peripheral Artery Disease V: Postoperative Nursing Management
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...